Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Clincal trial highlights in breast cancer at ESMO 2022

Paolo Tarantino • 12 Sep 2022
ESMO 2022
Breast Cancer Antibodies Sacituzumab govitecan Trastuzumab deruxtecan
MONARCH 3 TROPiCS-02

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, discusses some of the key trial data in breast cancer presented at ESMO 2022, including overall survival results from TROPiCS-02 (NCT03901339) and MONARCH 3 (NCT02246621). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Paolo Tarantino

Treatment options for advanced breast cancer: navigating the complex world of ADCs
1:14
Treatment options for advanced breast cancer: navigating the complex world of ADCs
Paolo Tarantino • 1 Jun 2025
DATO-Base: investigating Dato-DXd in HER2- breast cancer brain metastases
1:02
DATO-Base: investigating Dato-DXd in HER2- breast cancer brain metastases
Paolo Tarantino • 1 Jun 2025
Gene signatures and stromal TILs in stage I triple-negative breast cancer
1:18
Gene signatures and stromal TILs in stage I triple-negative breast cancer
Paolo Tarantino • 1 Jun 2025
Predictive biomarkers for T-DXd response in metastatic breast cancer
1:18
Predictive biomarkers for T-DXd response in metastatic breast cancer
Paolo Tarantino • 1 Jun 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals